EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Targeted therapy in acute myeloid leukemia: Resistance and overcoming strategy

Feifeng Song, Sisi Lin, Tong Xu, Chang Yang, Bold Sharavyn, Hua Naranmandura, Yiwen Zhang, Ping Huang

Drug Resistance Updates · 2025-11 · 83 · 101286

DOI: 10.1016/j.drup.2025.101286 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Drug Resistance Updates, 2025-11. Verfasst von Feifeng Song und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou M…. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Drug Resistance, Neoplasm, Molecular Targeted Therapy, Antineoplastic Agents. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 310 Literaturangaben. Gefördert von: Zhejiang Provincial Program for the Cultivation of High-Level Innovative Health Talents, National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acute myeloid leukemia (AML) is an aggressive hematological malignancy characterized by uncontrolled proliferation of immature myeloid blasts, leading to hematopoietic suppression and bone marrow failure. Advances in understanding the pathogenesis of AML have fueled the development of precision medicine approaches, with notable successes in targeting specific mutant proteins (e.g., FLT3, IDH1, IDH2), apoptotic regulators (e.g., BCL-2, MCL1), and cell-surface antigens (e.g., CD33, CD123, CD47). These targeted inhibitors exhibit moderate antileukemic activity as monotherapies and their clinical responses are often limited due to the emergence of drug resistance and disease relapse. Nevertheless, synergistic effects have been observed when these agents are combined with conventional chemotherapy or oncogenic pathway inhibitors. This review analyzes the current limitations of targeted therapies and explores multifaceted resistance drivers, encompassing on-target mutations, compensatory signaling pathway activation, drug-efflux mechanisms mediated by metabolic enzymes or transporters, intrinsic adaptive changes, and interactions with the tumor microenvironment. Corresponding therapeutic counterstrategies are also examined, such as mutation-specific molecular targeting, combinatorial suppression of alternative pathways, disruption of intrinsic adaptive responses, and immunotherapeutic approaches. These evolving interventions aim to overcome specific resistance mechanisms and reduce relapse rates. Future research integrating these strategies holds significant promise for addressing persistent challenges in AML management, ultimately advancing treatment paradigms and patient survival.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteDrug Resistance, NeoplasmMolecular Targeted TherapyAntineoplastic AgentsHumansTumor MicroenvironmentSignal TransductionMutationAntineoplastic Combined Chemotherapy ProtocolsPrecision Medicine

Stichwörter der Autor:innen

Acute myeloid leukemia (AML)ImmunotherapyOvercome strategiesResistance mechanismTargeted drugs

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou 310014, China; Zhejiang Provincial Clinical R…
  • Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou 310014, China.
  • College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
  • Department of Pharmacology, Mongolian National University of Medical Sciences, Ulan Bator, Mongolia.

Förderung

  • Zhejiang Provincial Program for the Cultivation of High-Level Innovative Health Talents
  • National Key Research and Development Program of China

Zitieren

APA

Song, F., Lin, S., Xu, T., Yang, C., Sharavyn, B., Naranmandura, H., Zhang, Y., & Huang, P. (2025). Targeted therapy in acute myeloid leukemia: Resistance and overcoming strategy. Drug Resistance Updates, 83, 101286. https://doi.org/10.1016/j.drup.2025.101286

Vancouver

Song F, Lin S, Xu T, Yang C, Sharavyn B, Naranmandura H, et al. Targeted therapy in acute myeloid leukemia: Resistance and overcoming strategy. Drug Resistance Updates. 2025;83:101286. doi:10.1016/j.drup.2025.101286

BibTeX
@article{Song2025,
  author = {Song, Feifeng and Lin, Sisi and Xu, Tong and Yang, Chang and Sharavyn, Bold and Naranmandura, Hua and Zhang, Yiwen and Huang, Ping},
  title = {Targeted therapy in acute myeloid leukemia: Resistance and overcoming strategy},
  journal = {Drug Resistance Updates},
  year = {2025},
  volume = {83},
  pages = {101286},
  doi = {10.1016/j.drup.2025.101286}
}
Kostenlos starten →